JAK/STAT pathway inhibition has been studied in pre-clinical models of NSCLC and has been shown to overcome resistance to cisplatin [42] and to enhance the anti-tumor activity of cetuximab [43]. This evidence concerns the gene SOAT1 and non-small cell lung carcinoma.